Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2008, Article ID 819123, 2 pages
http://dx.doi.org/10.1155/2008/819123
Review Article

Fulminant Type 1 Diabetes as a Model of Nature to Explore the Role of C-Peptide

First Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan

Received 27 November 2007; Accepted 26 February 2008

Academic Editor: Thomas Forst

Copyright © 2008 Yuko Murase-Mishiba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Imagawa, T. Hanafusa, J. Miyagawa, and Y. Matsuzawa, “A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies,” The New England Journal of Medicine, vol. 342, no. 5, pp. 301–307, 2000. View at Publisher · View at Google Scholar
  2. A. Imagawa, T. Hanafusa, Y. Uchigata et al., “Fulminant type 1 diabetes. A nationwide survey in Japan,” Diabetes Care, vol. 26, no. 8, pp. 2345–2352, 2003. View at Publisher · View at Google Scholar
  3. Y. Murase, A. Imagawa, T. Hanafusa et al., “Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy—a nationwide 5-year-study in Japan,” Diabetologia, vol. 50, no. 3, pp. 531–537, 2007. View at Publisher · View at Google Scholar
  4. T. Hanafusa, A. Imagawa, H. Iwahashi et al., “Report of the committee of the Japan diabetes society on research on fulminant type 1 diabetes mellitus: analysis of HLA serotype and diabetic microangiopathy,” Journal of the Japan Diabetic Society, vol. 50, pp. 825–833, 2007, Japanese. View at Google Scholar
  5. The Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar
  6. The Diabetes Control and Complications Trial Research Group, “Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial,” Annals of Internal Medicine, vol. 128, no. 7, pp. 517–523, 1998. View at Google Scholar
  7. Y. Ido, A. Vindigni, K. Chang et al., “Prevention of vascular and neural dysfunction in diabetic rats by C-peptide,” Science, vol. 277, no. 5325, pp. 563–566, 1997. View at Publisher · View at Google Scholar
  8. B. L. Johansson, K. Borg, E. Fernqvist-Forbes, A. Kernell, T. Odergren, and J. Wahren, “Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus,” Diabetic Medicine, vol. 17, no. 3, pp. 181–189, 2000. View at Publisher · View at Google Scholar